renal cell carcinoma

Biotech

FDA sinks Allarity’s plans for lead oncology asset

After a meeting with the FDA, Allarity Therapeutics is abandoning hope that its lead clinical asset could be sold as a monotherapy for kidney cancer.
Gabrielle Masson Aug 2, 2022 2:41pm

Despite 0% response rate, 4D hits primary goal in cancer trial

Mar 23, 2022 7:45am

FDA allows Allogene to resume CAR-T trials after safety scare

Jan 10, 2022 10:16am

Chasing Merck, Arrowhead posts early data on anti-cancer RNAi

Jul 7, 2021 9:00am

Calithera flunks phase 2 cancer trial, axes 35% of staff

Jan 4, 2021 8:23am

Merck backs up Peloton buyout with promising kidney cancer data

May 13, 2020 5:00pm